Tag: loncastuximab tesirine
Swedish Sobi to License Loncastuximab Tesirine from ADC Therapeutics
Swedish Orphan Biovitrum (Sobi®) has signed an exclusive license agreement with ADC Therapeutics to develop and commercialize loncastuximab tesirine (Zynlonta®) for use in hematologic...
ADC Therapeutics and Mitsubishi Tanabe Pharma Sign Exclusive License Agreement to...
ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation have signed an exclusive license agreement for the development and commercialization of loncastuximab tesirine (ADCT-402; Zynlonta®; ADC...
European Commission Grants Orphan Drug Designation to Loncastuximab Tesirine
The European Commission has granted Orphan Drug Designation to loncastuximab tesirine (Zynlonta®; ADC Therapeutics); previously known as ADCT-402, a CD19-targeted ADC, for the treatment...
Withdrawal of FDA’s Accelerate Approved Therapeutic Agents may harm Patients
The United States Food and Drug Administration’s (FDA) program to accelerate approval of some promising therapeutic agents has recently come under fire due to...
Sterling Pharma Solutions Acquires ADC Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...
FDA Approves Loncastuximab Tesirine in Treatment of Relapsed or Refractory Diffuse...
Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common form of blood cancer. Lymphomas occur when cells of the...
U.S. FDA Accepts Biologics License Application and Grants Priority Review for...
The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for loncastuximab tesirine, previously known as ADCT-402.
The investigational agent is...
FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab...
The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab tesirine, previously know as ADCT-402,...
First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...
Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
ADC Therapeutics Completes U.S. $ 267 Million Initial Public Offering
Earlier today, New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, confirmed that ADC Therapeutics (Lausanne; Biopôle, Switzerland),...
